Salute e Benessere

Meril Presents Successful LANDMARK RCT One-Year Results at Prestigious EuroPCR…

The Myval THV series demonstrated non-inferiority to contemporary THVs in terms of 1-year clinical efficacy composite endpoint (Myval THV Series: 13% vs. Contemporary THV: 13.1%, difference: -0.1%, one-sided 95% CI: 3.9%, Pnoninferiority < 0.0001). The Myval THV series demonstrated non-inferiority to contemporary THVs in terms of 1-year clinical efficacy composite endpoint (Myval THV Series: 13% vs. Contemporary THV: 13.1%, difference: -0.1%, one-sided 95% CI: 3.9%, Pnoninferiority <…
PR Newswire
22/05/2025

Tilray Medical Brings Canada's Iconic Cannabis Brand Good Supply to Germany

Denise Faltischek, Chief Strategy Officer and Head of International at Tilray Brands, stated, “With recent advancements in the medical cannabis industry, including enhanced formulations and broader availability, our goal remains steadfast—to provide patients in Germany with accessible, high-quality, and affordable medical cannabis solutions. The introduction of Good Supply in Germany reflects our commitment to improving patient care and empowering healthcare professionals with innovative...
Nasdaq GlobeNewswire
22/05/2025

Peristaltic Pumps Market worth $2.38 billion in 2030 - Exclusive Report by…

Browse in-depth TOC on "Peristaltic Pumps Market" Browse in-depth TOC on "Peristaltic Pumps Market" 180 – Tables 70 – Figures 270 – Pages Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=194304410 Tube pumps segment accounted for largest share of peristaltic pumps market in 2024 In 2024, the tube pumps segment held the largest share of the global peristaltic pumps market, driven by their versatility, cost-effectiveness, and ease of...
PR Newswire
22/05/2025

EdgeCap-backed Comac Medical Group Expands with Acquisition of ILIFE Consulting…

The transaction represents a significant milestone for the Group on its journey to becoming the leading pan-European full-service CRO partner for small and medium-sized biopharma companies, and complements recent expansions into the United States, Germany, and the United Kingdom. The transaction represents a significant milestone for the Group on its journey to becoming the leading pan-European full-service CRO partner for small and medium-sized biopharma companies, and complements recent...
PR Newswire
22/05/2025

Disclosure of voting rights at AGM in Vistin Pharma ASA

In relation to the Annual General Meeting in Vistin Pharma ASA (OSE: VISTN), on the 22th of May, the Company's Chair of the Board, Øyvin Brøymer, has received open proxies to represent a total of 5 156 012 shares in the Company at the AGM, corresponding to 11.63% of the total number of votes and shares in the Company. Together with the 14 509 280 shares held by Øyvin Brøymer through Intertrade Shipping AS, he will represent a total of 19 665 292 votes at the AGM, corresponding to a total of...
Nasdaq GlobeNewswire
22/05/2025

PCI Biotech: Minutes of Annual General Meeting 2025

All the matters on the agenda were approved and the minutes of the Annual General Meeting are attached to this release and are available on www.pcibiotech.com. Contact information: PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo Ronny Skuggedal, CEO / CFO, [email protected], Mobile: +47 9400 5757This information is subject to a duty of disclosure pursuant to Section 5-12 of the Norwegian Securities Trading Act. Attachment PCI Biotech Minutes AGM 22 May...
Nasdaq GlobeNewswire
22/05/2025

Zentiva and Euractiv Bring Policymakers Together for Health Policy Conference

Representing Europe's off-patent medicine sector, Steffen Saltofte called for a unified approach to reshape pharmaceutical policy with patients at the centre. He emphasised the need to bring together all healthcare stakeholders — from innovators to the off-patent industry, from regulators to policymakers — to fulfil the promise of health as a fundamental right for all. Representing Europe's off-patent medicine sector, Steffen Saltofte called for a unified approach to reshape pharmaceutical...
PR Newswire
22/05/2025

€2.6 million innovation challenge launches in Sub-Saharan Africa to reimagine…

While becoming a parent is a time of joy, it is also a period of significant change and vulnerability, where many need support for their mental, social and physical wellbeing. While becoming a parent is a time of joy, it is also a period of significant change and vulnerability, where many need support for their mental, social and physical wellbeing. Despite this, communities across Sub-Saharan Africa lack access to effective interventions that champion their wellbeing. Research has found...
PR Newswire
22/05/2025

€2.6 million innovation challenge launches in Southeast Asia to reimagine…

While becoming a parent is a time of joy, it is also a period of significant change and vulnerability, where many need support for their mental, social and physical wellbeing. While becoming a parent is a time of joy, it is also a period of significant change and vulnerability, where many need support for their mental, social and physical wellbeing. Despite this, communities acrossSoutheast Asialack access to effective interventions that champion their wellbeing. Research by Milieu has...
PR Newswire
22/05/2025

PROVISION Study Which Met Its Primary Endpoint Now Demonstrates Similar Clinical…

The PROVISION Study is the first Japanese prospective randomized controlled trial (RCT) comparing the outcomes of an angio-based technology compared to invasive wire-based physiology and enrolled 401 patients across 13 centers in Japan. Patients with intermediate coronary lesions (30-90% diameter stenosis) were randomized 1:1 to either the wire-based FFR arm, in which the treatment decision was determined based on FFR values obtained using an invasive pressure wire, or the FFRangio arm, in which…
PR Newswire
22/05/2025

Dynavox Group: New study in Germany validates life-changing effects and positive…

Nearly doubled quality of life for usersLike the study in Sweden, the German research shows that overall quality of life is almost doubled among users with a communication aid, compared to how life would have been without it. Among the main benefits expressed by users in Germany: Nearly doubled quality of life for usersLike the study inSweden, the German research shows thatoverall quality of life is almost doubledamong users with a communication aid, compared to how life would have...
PR Newswire
22/05/2025

Orion to host Capital Markets Day today, 22 May 2025, in Helsinki

ORION CORPORATIONINVESTOR NEWS22 MAY 2025 at 10.15 EEST Orion to host Capital Markets Day today, 22 May 2025, in Helsinki Orion hosts its Capital Markets Day for analysts, institutional investors, bankers, and media representatives in Helsinki today, 22 May 2025. At the event, members of the Orion Executive Management Board will discuss Orion's growth strategy, financial objectives, and businesses. Orion will not publish new strategic or financial targets in connection with...
Nasdaq GlobeNewswire
22/05/2025

LIfT BioSciences presents preclinical data on its first-in-class…

London, 22 May 2025– LIfT BioSciences, ('LIfT' or 'the Company'), a rapidly emerging biotech and the global leader in neutrophil immunotherapies, today announces that preclinical data showing the wider therapeutic potential of its first-in-class Immunomodulatory Alpha Neutrophils (IMANs) was presented at the American Society of Gene & Cell Therapy (ASGCT) 28 thAnnual Meeting held from from 13 – 17 May in New Orleans, USA.The poster highlights how IMANs, while demonstrating strong...
Nasdaq GlobeNewswire
22/05/2025

IBA Business Update Q1 2025

Year starting on trackLouvain-la-Neuve, Belgium, 22 May 2025- IBA (Ion Beam Applications S.A), the world leader in particle accelerator technology, today announces its business update for the first quarter of 2025.Group Overview Solid commercial momentum, particularly in IBA Clinical Equipment and Services backlog at €1.5 billion, with conversion executed in line with plan€ 9 million1 positive net cash position, decreasing vs. year-end. Foreseen backlog delivery...
Nasdaq GlobeNewswire
22/05/2025

Clue Reaches 1 Million Paid Subscribers, Cementing Position as Leading…

As consumers increasingly seek digital tools to manage their health proactively, women are turning to technology for insights into their reproductive health. Recent studies show that 78% of women experience cycle-related symptoms that impact their quality of life, yet traditional healthcare systems often fail to address these concerns adequately."Reaching one million paid subscribers represents more than just a business milestone," said Rhiannon White, CEO of Clue. "It validates…
Nasdaq GlobeNewswire
22/05/2025

AnnJi Pharmaceutical Company Announces Positive Phase 1/2a Results for AJ201 in…

The safety and pharmacokinetic profiles in SBMA patients were consistent with prior healthy volunteer data. AJ201 was generally well tolerated, and no systemic drug accumulation was observed. The safety and pharmacokinetic profiles in SBMA patients were consistent with prior healthy volunteer data. AJ201 was generally well tolerated, and no systemic drug accumulation was observed. Positive Clinical Signals After 12 weeks of oral treatment, AJ201 recipients showed clinically meaningful...
PR Newswire
22/05/2025

Press Release: Sanofi to acquire Vigil Neuroscience, Inc., adding a new…

Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer's disease to the neurology pipeline Paris, May 22, 2025.Sanofi announced today that it has entered into an agreement to acquire Vigil Neuroscience, Inc. (“Vigil”), a publicly traded clinical-stage biotechnology company focused on developing novel therapies for neurodegenerative diseases. This acquisition in neurology, one of Sanofi's four strategic disease areas, enhances Sanofi's...
Nasdaq GlobeNewswire
22/05/2025

Migraine Market Enters New Era Following Satsuma Pharmaceuticals' ATZUMI and…

Current migraine management involves a dual approach—acute treatment to relieve symptoms during an attack, and preventive strategies to reduce the frequency and intensity of future episodes. Acute therapies generally include triptans, nonsteroidal anti-inflammatory drugs (NSAIDs), and anti-nausea medications, which target symptoms like pain and nausea. Recently, more focus has been placed on preventive care for patients with frequent or debilitating migraines. This includes the use of…
PR Newswire
21/05/2025

Cellectis' Annual Shareholders General Meeting to be Held on June 26, 2025

The notice convening the annual general meeting stating the detailed agenda and modalities of participation in the meeting and the report of the board of directors to the shareholders meeting are available on the Cellectis website:https://www.cellectis.com/en/investors/general-meetings/About Cellectis Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. The company utilizes an allogeneic...
Nasdaq GlobeNewswire
21/05/2025

Jazz Pharmaceuticals to Participate in Upcoming June Investor Conferences

Goldman Sachs 46th Annual Global Healthcare Conference on Wednesday, June 11, 2025 Goldman Sachs 46 thAnnual Global Healthcare Conference onWednesday, June 11, 2025 Audio webcasts of the presentations will be available via the Investors section of the Jazz Pharmaceuticals website athttps://investor.jazzpharma.com/investors/events-presentations. A replay of the webcasts will be archived on the website for 30 days. About Jazz Pharmaceuticals Jazz Pharmaceuticals plc (Nasdaq:...
PR Newswire
21/05/2025

Nanobiotix Provides First Quarter 2025 Operational and Financial Update

Dosing of a first patient in the CONVERGE study, a Phase 2 randomized controlled clinical trial for patients with stage 3 unresectable non-small cell lung cancerPresentation of data at the European Lung Cancer Conference in a Phase 1 study of re-irradiation with JNJ-1900 (NBTXR3) in locoregional recurrent NSCLC and a Phase 1 study of JNJ-1900 (NBTXR3) in combination with nivolumab or pembrolizumab for patients with lung metastases from NSCLC or other solid tumorsStrengthened financial...
Nasdaq GlobeNewswire
21/05/2025

BCC Research Forecasts Neurology Market to Reach $94.8 Billion by 2029

This report covers the market's current and future potential and examines market drivers and constraints, pipeline medications, the competitive landscape, the regulatory picture, and the epidemiology of neurological disorders. The study segments the market by disease indications, including Parkinson's, Alzheimer's, psychotic disorders, epilepsy, autism, multiple sclerosis, and brain tumors, with therapeutic and regional analysis for each. It also profiles smarket participants and competitors…
PR Newswire
21/05/2025

OSE Immunotherapeutics Announces Strategic Collaboration to Pioneer Novel mRNA…

OSE Immunotherapeutics Announces Strategic Collaboration to Pioneer Novel mRNA TechnologiesOSE Immunotherapeutics to lead French consortium with Inside Therapeutics and MiNT Laboratory (University of Angers) secures €1.3 million in funding fromBpifrance and Région Pays de la Loire NANTES, France – May 21, 2025, 6:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today announces a strategic collaboration with Angoulême/Bordeaux- based Inside Therapeutics and...
Nasdaq GlobeNewswire
21/05/2025

Ipsen S.A. - Annual General Meeting held on 21 May 2025

Annual General Meeting of Ipsen S.A. held on 21 May 2025All the resolutions submitted to the shareholders' vote have been adopted PARIS, FRANCE, 21 May 2025 -Ipsen (Euronext: IPN; ADR: IPSEY) announces today that the Annual General Meeting of the Company was held on Wednesday 21 May, 2025 at theSalons de l'Hôtel des Arts et Métiers, 9 bis, avenue d'Iéna, 75116 Paris (France), under the chairmanship of Mr. Marc de GARIDEL, Chairman of the Board of Directors,...
Nasdaq GlobeNewswire
21/05/2025
Altri  Comunicati